Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AtheroGenics, Inc.
Inflammatory disease pharmaceutical company announces pricing of $80M offering
September 10th, 2003
AtheroGenics, Inc., (AGIX) announced that it has agreed to privately place $80 million aggregate principal amount of its convertible notes due 2008. The notes will be convertible into AtheroGenics common stock at a conversion rate of 65.1890 shares per $1,000 principal amount of notes (reflecting a premium of approximately 22.5% relative to the NASDAQ closing price for AGIX common stock of $12.52 on August 13, 2003), and will bear interest at a rate of 4.50% per annum. AtheroGenics has granted the initial purchasers of the notes a 30-day option to purchase an additional $20 million principal amount of the notes. The placement of the notes is expected to close on August...
Source: Biotech Week (2003-09-10)
|
